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Amyotrophic lateral sclerosis (ALS) is a rapidly pro-
gressing neurodegenerative disease, characterized
by motor neuron (MN) death, for which there are no
truly effective treatments. Here, we describe a new
small molecule survival screen carried out using
MNs from both wild-type and mutant SOD1 mouse
embryonic stem cells. Among the hits we found,
kenpaullone had a particularly impressive ability to
prolong the healthy survival of both types of MNs
that can be attributed to its dual inhibition of GSK-3
and HGK kinases. Furthermore, kenpaullone also
strongly improved the survival of human MNs
derived from ALS-patient-induced pluripotent stem
cells and was more active than either of two com-
pounds, olesoxime and dexpramipexole, that
recently failed in ALS clinical trials. Our studies
demonstrate the value of a stem cell approach
to drug discovery and point to a new paradigm for
identification and preclinical testing of future ALS
therapeutics.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a fatal, late-onset disease
that causes degeneration of both upper and lower motor
neurons (MNs). ALS generally progresses rapidly, with a mean
survival time of between 3 and 5 years. Approximately 10% of
cases are familial (inherited), and 20% of these are caused by
mutations in the SOD1 gene (Brown, 1997; Boille´e et al., 2006).
Although SOD1-associated ALS accounts for only 2% of all
cases, it has been the most studied form due to the early discov-
ery of disease-causing mutations and the availability of mouse
models. Mutations in the SOD1 gene cause a gain of toxic, ratherthan a loss of normal, function. Exactly how this causes MN
death is still unclear, but it is now well accepted that cell-auton-
omous and non-cell-autonomous mechanisms can contribute to
degeneration (Di Giorgio et al., 2007; Nagai et al., 2007; Ilieva
et al., 2009). A more recent breakthrough has identified TAR-
DNA binding protein-43 (TDP-43) as a major component of
protein aggregates found in sporadic ALS and non-SOD1 familial
ALS cases (Arai et al., 2006; Neumann et al., 2006). Mutations
in TARDBP, the gene encoding TDP-43, were found in 4% of
familial ALS cases (Van Deerlin et al., 2008). Further, a hexanu-
cleotide repeat expansion within the C9orf72 gene has recently
been identified as the most frequent pathogenic cause of ALS
thus far, accounting for about 6% of sporadic ALS cases, and
36%–40% of familial ALS cases in Europe and the USA (Renton
et al., 2011; Majounie et al., 2012). Thus, there may be numerous
pathogenic initiators of ALS, including oxidative stress, protein
misfolding and aggregation, RNA processing, mitochondrial
dysfunction, excitotoxicity, neuroinflammation, axonal transport
defects, and neurotrophin depletion (Joyce et al., 2011).
Riluzole is currently the only approved treatment for ALS. It is
thought to act by reducing an excitotoxic component of the
disease, but prolongs life by only 2–3 months and provides little
functional improvement (Miller et al., 2007). While there has been
a great deal of effort to discover better treatments, both olesox-
ime and dexpramipexole (Cudkowicz et al., 2011; Sunyach et al.,
2012), two promising compounds, failed in phase III ALS trials
just in the past year. Both had been tested in a mouse model
of ALS, but neither had been tested on rodent ALS MNs. Need-
less to say, neither had been tested on any type of human MN
in vitro either. Thus, it may be that having better methods for
identifying promising drug candidates for ALS and rigorously
evaluating them in vitro prior to testing them in the clinic would
greatly improve the chances of discovering better treatments
for this disease.
In the last few years, simple protocols for differentiatingmouse
and human embryonic stem cells (ESCs) and induced pluripotent
stem cells (iPSCs) into MNs have become available (Wichterle
et al., 2002; Miles et al., 2004; Boulting et al., 2011). For theCell Stem Cell 12, 713–726, June 6, 2013 ª2013 Elsevier Inc. 713
Figure 1. Identification of Small Molecules that Promote the Survival of ESC-Derived MNs
(A) Overview of directed differentiation and MN screening flow. Ag, Shh agonist; RA, retinoic acid. Scale bar represents 200 mm.
(B) Plate layout in the form of a heat map of a 384-well screening plate. Positive controls are in left top (TF/+cycloheximide) and right (+TF) columns and negative
controls (TF, DMSO-treated) are in left bottom. Representative images ofHB9::GFPMNs are shown for controls and for a hit well in which cells were treatedwith
kenpaullone. Each image shown represents a field taken within an individual well (approximately one-twelfth of the well). Scale bar represents 200 mm.
(C) Scatter plots showing screening results (points in red correspond to individual library compounds).
(legend continued on next page)
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type mouse ESCs and from mouse ESCs carrying a human
SOD1G93A transgene (Di Giorgio et al., 2007) and used both in
trophic factor withdrawal screens to identify small molecules
that promote MN survival. Of the compounds that increased sur-
vival of both cell types, the multikinase inhibitor kenpaullone
stood out. A variety of experiments showed that kenpaullone
not only keeps MNs alive for several weeks in the absence of
added trophic support, but maintains neuritic processes, synap-
ses, and normal electrophysiological characteristics. We show
that kenpaullone’s potent effects are mediated via dual inhibition
of GSK-3a/b and HPK1/GCK-like kinase (HGK; also known as
MAP4K4), a kinase upstream in the phospho-c-Jun-mediated
neuronal apoptosis pathway (Yao et al., 1999). Furthermore,
kenpaullone was also able to improve survival of MNs produced
from wild-type and two different types of ALS-patient-derived
iPSCs, while olesoxime and dexpramipexole were less effective.
In that regard, although kenpaullone was simply a hit compound
from our screen and not chemically optimized in any way, it was
superior to two compounds recently tested in the clinic.
RESULTS
Assay Development for MN Survival Screens
We produced MNs from both wild-type (Hb9::GFP) and
SOD1G93A (SOD1G93A/HB9::GFP) mouse ESCs using modifica-
tions of standard protocols (Figure 1A and Experimental Proce-
dures) and were able to generate cultures with 30%–50%
MNs. As reported by Di Giorgio et al. (2007), we found that there
was no significant difference in basal survival betweenHB9::GFP
andSOD1G93A/HB9::GFP cultures in the first week, although sur-
vival of SOD1G93A/HB9::GFPMNswas somewhat more variable.
We chose a standard model of inducing death—trophic factor
withdrawal—and applied it to both types of MNs. Various plating
densities and times for initiation and duration of trophic factor
withdrawal were optimized for a 384-well HTS format, so that
we achieved 80% MN death in 3 days (Figure S1 available
online). Cycloheximide (CHX), a protein synthesis inhibitor that
blocks apoptosis (Mattson and Furukawa, 1997), was identified
as a hit in a trial screen (Figure S1C) and was used as a positive
control compound.
Identification of Compounds that Promote MN Survival
A collection of approximately 5,000 small molecule compounds
including known drugs, bioactives, and other annotated chemi-
cals was screened at three concentrations (Figures 1B and
1C). Hits were defined as compounds that both robustly
increased the number of surviving MNs compared to wells
without trophic factors and preserved cell morphology (size of
soma and presence of neurites; Figure 1E). Hit compounds
from the primary screen were retested in dose-response survival(D) Dose curves of a compound that scored only inHB9::GFPMNs (Tyrphostin A9
two compounds that scored in both HB9::GFP and SOD1G93A/HB9::GFP MNs (ke
HB9::GFP and SOD1G93A/HB9::GFP screens, average MN survival in negative c
(E) Image-based analyses allowed for excluding putative hit compounds that did
preserved normal cell morphology, including an intact neurite network (arrows: ex
an increased number of MNs, but mostly with small soma and few neurites. Sca
See also Figure S1 and Table S1.assays and then categorized by annotated activities. A sig-
nificant number of hits or hit categories for HB9::GFP or
SOD1G93A/HB9::GFP MNs act on targets previously shown to
be neuroprotective or involved in ALS. Nine compounds that
inhibit protein or DNA synthesis improved survival of one or
both types of MNs. These compounds are well known to be
antiapoptotic (Mattson and Furukawa, 1997; Martin, 2001). The
matrix metalloproteinase (MMP) inhibitor 1,10-phenanthroline
monohydrate promoted the survival of both types of MNs.
MMPs have been implicated in MN degeneration in ALS, and
MMP inhibitors have been shown to extend the survival of
ALS mice (Lorenzl et al., 2006; Niebroj-Dobosz et al., 2010).
CP55940 (a cannabinoid receptor agonist) promoted the survival
of both MN types (Figure 1D). Cannabinoid receptors have pre-
viously been shown to be elevated in spinal cords of symptom-
atic SOD1G93A mice, and treatment with cannabinoid receptor
agonists delayed disease onset and prolonged survival (Kim
et al., 2006; Shoemaker et al., 2007). Additionally, the calpain
inhibitor MDL 28170 promoted survival of SOD1G93A/HB9::GFP
MNs (Figure 1D), consistent with studies in which calpain inhibi-
tion prolonged the viability of SOD1G93A MNs in culture and the
life span of SOD1G93A mice (Wootz et al., 2006; Tradewell and
Durham, 2010). Ligands for neurotransmitter receptors (e.g., A
77636 hydrochloride and 3-Tropanylindole-3-carboxylate me-
thiodide) and compounds targeting calcium channels (e.g., the
calcium agonist FPL-64176) also scored as hits in one or both
types of MNs. This came as no surprise because neuronal activ-
ity and calcium flux are crucial regulators for neuronal survival,
and ALS is known to involve the dysregulation of both (Sandyk,
2006; Grosskreutz et al., 2010). Finally, hit compounds included
several kinase inhibitors. Tyrphostin A9 (a multikinase inhibitor)
promoted survival of HB9::GFP MNs alone, while kenpaullone
(annotated as a GSK-3 inhibitor) strongly increased survival of
both MN types (Figure 1D). We chose to pursue compounds
that affected both MN types reproducibly, since they might
have the best chance of working broadly across different ALS
disease types (these hits are listed in Table S1).
Kenpaullone and Some Other GSK-3 Inhibitors
Promote Survival
In followup studies, we focused on kenpaullone, the compound
that consistently rescued survival most effectively for wild-type
and mutant MNs. Kenpaullone reportedly acts on a biologically
meaningful and pharmacologically ‘‘druggable’’ target, GSK-3.
We therefore tested additional commercially available GSK-3
inhibitors in our survival assay. Several did promote survival,
but their effects were often weaker and more variable than
those of kenpaullone. Surprisingly, alsterpaullone, a close
structural relative of kenpaullone, was less consistent and
was often toxic at higher doses (Figure S2A). GSK-3 inhibitor
VIII (Anastassiadis et al., 2011) and GSK-3 inhibitor XIII showed), a compound that scored only in SOD1G93A/HB9::GFPMNs (MDL 28170), and
npaullone and CP55940). Data are presented as mean ± SD. Note that in both
ontrol wells (TF, DMSO-treated) was about 30% of that in +TF control wells.
not preserve MN integrity. Images shown here are of (left) a compound that
amples of visible neuronal processes), and (right) a compound that resulted in
le bar represents 100 mm.
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Figure 2. Kenpaullone Promotes MN Survival through a Cell-Autonomous Mechanism
(A) Survival effects of kenpaullone and more specific GSK-3 inhibitors, CHIR98014 and CHIR99021. Kenpaullone clearly has particularly strong activity. In
this experiment, the MN survival in TF/DMSO-treated controls was 18% (for HB9::GFP) and 35% (for SOD1G93A/HB9::GFP) of that in their respective +TF
controls.
(B) Reducing the number of progenitor cells using Ara-C does not diminish the effectiveness of kenpaullone. Olig2 staining was used to identify MN progenitors.
Ara-C treatment (between days 2 and 4) significantly reduced the number of Olig2+ cells (p < 0.01). At the same time, kenpaullone’s effect was not reduced by
Ara-C treatment; in fact, there was a small but statistically significant (two-way ANOVA, p = 0.0002) increase in MN survival by kenpaullone after Ara-C treatment.
Scale bar represents 200 mm.
(C) The effect of kenpaullone remains essentially unchanged in highly enriched Hb9::GFP MN cultures. FACS-purified MNs were treated with Ara-C to further
ensure that any residual progenitor cell proliferation would be minimized. Images show that these cultures had very few non-MNs. In spite of that, kenpaullone
was able to improve MN survival to a comparable degree to that observed in mixed cultures. Note that the MN survival in TF control was 38% of that in +TF
control in this experiment. Scale bar represents 100 mm.
Data in this figure are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t test, two-tailed, compared to TF controls). See also Figure S2.
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ures S2A). Still others, such as CHIR99021 and CHIR98014,
thought to be among the most specific inhibitors (Bain et al.,
2007), did not promote survival at all (Figure 2A). These exper-
iments suggested that while GSK-3 inhibition might play a role
in promoting survival, the particularly pronounced effect of
kenpaullone could have resulted from additional molecular
activities.716 Cell Stem Cell 12, 713–726, June 6, 2013 ª2013 Elsevier Inc.Kenpaullone Increases Survival, but Not the Production,
of New MNs
Recent publications suggest that GSK-3 may be involved in
regulating the proliferation and differentiation of neural progeni-
tors (Hur and Zhou, 2010; Lange et al., 2011). To confirm that the
increase in MN numbers produced by kenpaullone treatment
resulted from increased survival of existing MNs, we treated
cultures with the antimitotic agent Ara-C to eliminate dividing
Figure 3. Kenpaullone Treatment Improves Survival When MN Death Is Initiated by Other Perturbations
(A and B) Effects of kenpaullone and GSK-3 inhibitor VIII on MN death induced by PI3K inhibitors. LY294002 (A) or PI-103 (B) was added to cultures on day 4, with
or without concurrent treatment with 10 mM kenpaullone or 10 mM GSK-3 inhibitor VIII. Cells were fixed on day 7 for survival analysis. Survival is measured with
respect to cells treated with DMSO alone. *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t test, two-tailed, compared to 0 mM LY294002 or PI-103).
(C) Kenpaullone also blocks death of MNs accelerated by coculture with SOD1G93A astrocytes. Hb9::GFP MNs were FACS sorted and plated on a confluent
monolayer of wild-type or SOD1G93A astrocytes. Kenpaullone was added to cultures 24 hr later and was refreshed every 3 days by replacement of half of the old
mediumwith freshmedium containing 13 concentration of the compound. Cells were fixed after 9 days of compound treatment andMN survival was determined.
Trophic factors were present throughout the experiment. Data are presented as percent survival normalized to that of DMSO-treated MNs plated on wild-type
astrocytes. Again, kenpaullone was effective in decreasing the extent of death.
Data are presented as mean ± SEM. See also Figure S3.
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(Figure 2B). While treatment with Ara-C significantly reduced
the number of Olig2+ progenitor cells, it was in fact associated
with a small increase in the effect of kenpaullone. We also
used BrdU to label proliferating cells and any MNs derived
from them (Figures S2B and S2C). We did not find any BrdU/
GFP double-positive cells. These studies strengthen the conclu-
sion that kenpaullone has a genuine survival-promoting effect.
The Effect of Kenpaullone Is Cell Autonomous
ESC-derived MN cultures are heterogeneous, containing 50%–
70% nonneuronal cells or other types of neurons. To determine
if kenpaullone exerts its protective effect in a cell-autonomous
or non-cell-autonomous way, we used FACS to purify MNs
based on their Hb9::GFP expression and established highly
enriched cultures (Figure 2C). We then treated them with Ara-C
to further limit the number of proliferating progenitors. When
trophic factors were removed from these cultures, kenpaullonetreatment still promoted survival, with a dose curve similar to
that in mixed cultures. Thus, kenpaullone seems to act on MNs
themselves.
Kenpaullone Also Promotes Survival When Death Is
Initiated by Other Types of Stimuli
The PI3K/Akt pathway is well known to regulate neuronal sur-
vival, including that of MNs (Brunet et al., 2001; Barthe´le´my
et al., 2004). Furthermore, PI3K/Akt activity is decreased in
MNs of both sporadic and familial ALS patients, as well as in
mutant SOD1 mice (Koh et al., 2004; Dewil et al., 2007). We
sought to examine if kenpaullone or a more specific GSK-3
inhibitor (inhibitor VIII) could protect MNs from death caused
by inactivation of PI3K/AKT. The PI3K inhibitor LY294002
induced dose-dependent death in both HB9::GFP and
SOD1G93A/HB9::GFP MNs (Figure 3A). However, when kenpaul-
lone was coincubated with LY294002, MN death was signifi-
cantly attenuated. In contrast, although inhibitor VIII was ableCell Stem Cell 12, 713–726, June 6, 2013 ª2013 Elsevier Inc. 717
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produced only a very small increase in HB9::GFP MN survival
and did not have any noticeable effect on SOD1G93A/HB9::GFP
MNs. We also tested PI-103, a more potent and selective PI3K
inhibitor, with similar results (Figure 3B). Thus, kenpaullone’s
strong effects are not restricted to protection after trophic factor
withdrawal.
Several studies have shown that astrocytes derived from ALS
patients or animal models, especially mutant SOD1-bearing as-
trocytes, contribute to MN death (Di Giorgio et al., 2007, 2008;
Marchetto et al., 2008; Dı´az-Amarilla et al., 2011; Haidet-Phillips
et al., 2011). We also observed that HB9::GFP MNs plated on a
monolayer of SOD1G93A astrocytes survived less well than the
same cells plated on wild-type astrocytes, with the effect
becoming most obvious at later time points (Figure 3C). We
found that kenpaullone improved MN survival on both wild-
type and SOD1G93A astrocytes. In fact, kenpaullone treatment
allowed MNs to survive as well on SOD1G93A astrocytes as on
wild-type astrocytes. This result demonstrates that kenpaullone
is able to act even when death is triggered by ‘‘toxic’’ glial
factors.
Kenpaullone Promotes Long-TermSurvival ofWild-Type
and Mutant MNs in the Presence or Absence of Trophic
Factors
We analyzed whether kenpaullone was able to promote survival
in a trophic-factor-deficient environment for extended periods of
time (Figure S3A). At all time points examined, kenpaullone
improved survival of both HB9::GFP and SOD1G93A/HB9::GFP
MNs, but the effect was proportionally greater in SOD1G93A/
HB9::GFP cultures at the later time points perhaps because their
survival was additionally compromised. In addition, we found
that the basal level of cell death could be prevented by kenpaul-
lone treatment even when cells were kept in neurotrophin-
containing medium (Figure S3B). Under those conditions, as
previously reported (Di Giorgio et al., 2007), the amount of death
in SOD1G93A/HB9::GFP cultures began to exceed that in
HB9::GFP cultures after 2 weeks. As the relative death of
SOD1G93A/HB9::GFPMNs increased at those later times, the ef-
fect of kenpaullone again became relatively greater. By day 28,
there was an 8-fold increase in the number of SOD1G93A/
HB9::GFP MNs in medium with kenpaullone compared to me-
dium without, compared to a 2.9-fold enhanced survival of
wild-type MNs (Figure S3C).
Effect of Kenpaullone on MN Morphology and Function
To investigate whether MNs kept alive by kenpaullone in the
absence of neurotrophic factors are truly intact, we evaluated
a variety of morphological and electrophysiological properties
of the surviving cells. First, we found that kenpaullone supported
the structural integrity of MN processes even at extended time
points (Figures S4A–S4F). We also used an automated imager
to count the number of synapses perMN (defined as overlapping
regions positive for the presynaptic marker synapsin and the
postsynaptic marker PSD95 on individual MNs; Figure 4A).
Again, kenpaullone was able to preserve morphological synap-
ses on both MN types.
Next, we compared the electrophysiological properties of
MNs grown in complete medium with trophic factors (+TF) with718 Cell Stem Cell 12, 713–726, June 6, 2013 ª2013 Elsevier Inc.those of cells in trophic-factor-deficient (TF) medium, with or
without kenpaullone supplementation (Figures 4B and S4G).
Attempts to collect data from cells grown inTFmediumwithout
kenpaullone failed to obtain stable recordings despite a sig-
nificant number of patch attempts. However, when we carried
out whole-cell voltage-clamp recordings from MNs grown
in +TF medium or TF medium with kenpaullone, we found
no significant differences in their properties (Figure S4G). In
current-clamp mode, depolarizing stimuli elicited robust action
potentials in both groups. Two key measurements that reflect
neuronal health are the resting membrane potential and input
resistance, and we found that neither varied between the two
groups (Figure S4G). We also recorded responses to excitatory
neurotransmitters, such as kainate, and inhibitory transmitters,
such as GABA. Again, we found no significant differences
between groups. Together, these data show that kenpaullone
treatment preserves neuronal health when trophic factors are
removed.
Kenpaullone Decreases Mutant SOD1 Levels
Since enhanced death undergone bySOD1G93A/HB9::GFPMNs,
especially at later times, seems likely to relate to their expression
of high levels of SOD1G93A protein, one possibility is that
kenpaullone could act in part by reducing those levels. When
we added kenpaullone to cultures on day 4 and analyzed them
by western blot on day 21, we found that SOD1G93A levels
were sharply decreased both in the absence (Figure 5A) and in
the presence (Figure 5B) of trophic factors. Endogenous mouse
SOD1 protein was not affected (data not shown), nor was there
an effect on wild-type human SOD1 levels in cultures produced
from an ESC line that overexpresses wild-type human SOD1
(wtSOD1/Hb9::GFP) (Figures 5A and 5B). Furthermore, single-
cell confocal imaging revealed that SOD1G93A levels were
reduced in GFP+ MNs, both in the presence and in the absence
of trophic factors (Figure 5C).
It has been shown that SOD1G93A begins to accumulate in
ubiquitinated aggregates after 2 weeks of culture in neurotro-
phin-containing medium. This is approximately the time at which
the rate of death of the mutant MNs, relative to that of wild-type
MNs, begins to increase (Di Giorgio et al., 2007). We confirmed
the appearance of aggregates in our cultures at those later
time points (Figure 5C). We found no differences in mutant pro-
tein levels between untreated and kenpaullone-treated cultures
until at least 15 days of treatment (Figure S5A). We also
measured MN levels of ubiquitin by single-cell imaging and
found that it was reduced at days 21 and 28, but not at day 15,
regardless of the presence or absence of trophic factors (Fig-
ure S5B). Thus, in addition to its early survival promoting activity,
kenpaullone has a delayed effect on the accumulation of both
SOD1G93A and ubiquitin, decreasing both at around the time at
which proteins begin to aggregate and mutant MNs have an
accelerated rate of death.
Mechanistic Studies of Kenpaullone’s Activities
Kenpaullone is known to inhibit GSK-3, so we first sought
to determine the role of GSK-3 in MN survival in our assays.
To eliminate the possibility of functional redundancy, we
employed a lentiviral-mediated shRNA knockdown strategy to
reduce expression of both a and b isoforms of the enzyme
Figure 4. Kenpaullone Preserves Morphological and Functional Integrity of MNs Even after Long Treatment Periods
(A) Kenpaullone (5 mM) increases the number of synapses perMN, even when analyzed on day 21 (after 17 days of kenpaullone treatment). Images show synapsin
(yellow) and PSD95 (red) staining on a kenpaullone-treated MN. Arrows indicate examples of synapses on MNs. Data are presented as mean ± SEM. *p < 0.05
(Student’s t test, two-tailed). Scale bar represents 50 mm.
(B) Kenpaullone-treated MNs are electrophysiologically similar to those maintained in TFs. HB9::GFP MNs treated for 3 days in the absence of trophic factors
(TF/+kenpaullone) were compared to MNs that were grown in complete medium (+TF) in terms of functional sodium and potassium currents [1], action
potentials [2], response to excitatory neurotransmitter (kainate, 100 mM) [3], and response to inhibitory neurotransmitter (GABA, 100 mM) [4].
See also Figure S4.
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carrying a nonsilencing shRNA, less than 20% of MNs survived
trophic factor withdrawal (Figure S6B). In contrast, in cultures
receiving GSK-3 shRNAs, more than 50% of MNs survived.
This survival was significant, but still substantially lower than
that achieved with kenpaullone.
Since it was possible that we were unable to achieve higher
levels of survival using shRNAs because of incomplete knock-
downs, we used another approach to address the role of
GSK-3 in survival after trophic factor removal. We produced
MNs from the following mouse ESC lines: GSK3a / (GSK3a-
KO), GSK3b / (GSK3b-KO), and GSK3a +//GSK3b / (3/4-
KO). ESCs that are GSK3a //GSK3b / were not able to
differentiate into neurons (Doble et al., 2007). Since these MNs
do not carry an Hb9::GFP transgene, we counted MNs as Islet
(Isl)+/MAP2+ cells (Figures 6A and S6C). When deprived of
neurotrophins, 25% of wild-type MN cells survived, while 31%,
41%, and 57% of MNs in GSK3a-KO, GSK3b-KO and 3/4-KO
cultures survived (see Supplemental Experimental Procedures).
The improved, but not completely restored, survival of cells that
lack GSK-3a or/and GSK-3b again suggests that kenpaulloneenhances survival by interacting with targets in addition to
GSK-3. However, we cannot rule out the possibility that the
incomplete rescue was due to the residual copy of GSK-3a in
the 3/4-KOMNs.We also added kenpaullone to GSK-3-deficient
cultures to determine whether the compoundwould still enhance
survival. Interestingly, kenpaullone was still active, maintaining
the number of MNs close to that in cultures with trophic support
(Figures 6A). Thus, a variety of experimental results are consis-
tent with the idea that GSK-3 inhibition may account for part of
kenpaullone’s effect, but other activities are necessary to explain
its unique set of actions.
Additional Targets of Kenpaullone
We wished to identify additional molecular targets that might
be acted on by kenpaullone. Since kenpaullone is reported to
inhibit multiple kinases (Anastassiadis et al., 2011), we carried
out preliminary studies employing a Phospho-Kinase Antibody
Array to examine the site-specific phosphorylation of a variety
of kinases and their protein substrates in the presence or
absence of kenpaullone in MN cultures (data not shown; see
Supplemental Experimental Procedures). First, results indicatedCell Stem Cell 12, 713–726, June 6, 2013 ª2013 Elsevier Inc. 719
Figure 5. Kenpaullone Treatment Decreases Mutant SOD1 Protein Levels
(A and B) In both the absence (A) and the presence (B) of trophic factors, SOD1G93A protein, but notWT SOD1 protein, was decreased when cultures were treated
with kenpaullone and analyzed on day 21. The antibody used was specific for human SOD1, as is seen by the lack of staining on wild-type mouse MNs
(HB9::GFP).
(C) To confirm that the level of SOD1G93A protein was also decreased specifically in MNs, cultures were stained with an anti-human SOD1 antibody and analyzed
by single-cell imaging of GFP+ cells. By this analysis, again on day 21, the average amount of SOD1 per MNwas decreased by kenpaullone treatment in both +TF
and TF conditions. Insets show higher magnification of cells contained within white circles. Scale bar represents 50 mm.
Data are presented as mean ± SEM. p values were calculated with a two-tailed Student’s t test. n.s., not significant. See also Figure S5.
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confirming that kenpaullone inhibits activation of this kinase in
our assay. Further, results indicated reductions in the relative
phosphorylation of both c-Jun N-terminal kinase (JNK) and
c-Jun, respectively. Since phospho-c-Jun is well known to be
associated with stress-induced neuronal apoptosis and can
also be activated subsequent to trophic factor withdrawal
(Ham et al., 1995; Watson et al., 1998), we investigated this
finding more thoroughly.720 Cell Stem Cell 12, 713–726, June 6, 2013 ª2013 Elsevier Inc.For this set of experiments, we decided to compare the effects
of kenpaullone to those of CHIR99021, reported to be among
the most selective of GSK-3 inhibitors yet still unable to support
MN survival under our assay conditions (Figure 2A; Bain et al.,
2007). First, using immunostaining with phospho-specific anti-
bodies, we observed that kenpaullone, but not CHIR99021,
decreased the percentage of MNs positive for phospho-c-Jun
or phospho-JNK, even at very early time points, confirming
results of the Phosho-Kinase Antibody Array (Figures 6B and
Cell Stem Cell
Motor Neuron Screen for ALS Candidate Therapeutics6C). We next examined MKK4, an upstream regulator of this
pathway (Figure 6E), and found that its phosphorylation was
also suppressed (Figure 6B).
We next sought to determine which upstream kinase in this
particular pathway could be inhibited directly by kenpaullone.
According to prior reports on kinase activity, potential candi-
dates includemixed lineage kinase-3 (MLK3) and HGK (Anastas-
siadis et al., 2011). We therefore performed in vitro phosphoryla-
tion reactions using the two recombinant kinases, with a myelin
basic protein peptide as the substrate. Surprisingly, we found
that kenpaullone, but not CHIR99021, differentially inhibited
HGK, but not MLK3, activity (Figure 6D). Importantly, HGK is
highly expressed in adult mouse MNs (Allen Spinal Cord Atlas;
imageId = 100479716). To confirm and extend these results,
we performed the immunostaining studies with a site-specific
antibody against phospho-Tak1, an intermediate in the cell
death pathway between HGK and MKK4 (Yao et al., 1999), but
uninvolved in the pathway activated by MLK3. The proportion
of MNs immunopositive for phospho-Tak1 (Figure 6B) was
significantly reduced by kenpaullone, but not CHIR99021, incu-
bation. Together, these results indicate that the highly beneficial
effects of kenpaullone, when compared to other more specific
GSK-3 inhibitors, can be attributed in part to its reduction in
the activation of the HGK-Tak1-MKK4-JNK-c-Jun cell death
signaling cascade (Figure 6E).
Kenpaullone Promotes Survival of MNs Derived from
Human ALS iPSCs
For our results to be relevant to treating ALS, it is important to
demonstrate that they can be applied to human MNs. We first
produced MNs from a human ESC line expressing an HB9::GFP
transgene (HuES-3/Hb9::GFP; Di Giorgio et al., 2008) (Figure S7)
and FACS purified them to reduce the number of residual
progenitor cells and other types of neurons. We found that
kenpaullone treatment prevented these cells from dying after
the withdrawal of trophic factors (Figure 7A). For comparison,
we treated these cells with two compounds, olesoxime and
dexpramipexole (Cudkowicz et al., 2011; Sunyach et al., 2012),
that recently failed in phase III clinical trials for ALS. We found
that olesoxime had some survival-promoting effects, whereas
dexpramipexole had no significant activity on the HuES-3 MNs
(Figure 7A).
We then tested kenpaullone on MNs produced from iPSCs
from a control individual and from two ALS patients expressing
confirmed mutations in either SOD1 (Boulting et al., 2011) or in
TDP-43. In all human cultures, kenpaullone produced a sub-
stantial increase in MN survival whereas dexpramipexole was
virtually without effect on any of the humanMN types. Olesoxime
had a more positive effect, but was somewhat variable across
the different MN lines (Figures 7B–7D).
Discussion
ALS is a complicated, heterogeneous disease involving cell
autonomous (MN) and non-cell-autonomous (glial) elements.
This, as well as the historical lack of availability of large
numbers of mouse and human neural cells, has made thera-
peutics discovery and development difficult. For the data pre-
sented in this paper, we have taken advantage of our ability
to produce large numbers of mouse MNs from ESCs andhave carried out survival screens using both wild-type and
SOD1 mutant cells.
Our screening strategy is worthy of discussion. Recently,
Ho¨ing et al. (2012) described an intriguing screening assay using
stem-cell-derived MNs cocultured with a microglial cell line,
supporting the notion of carrying out screens using stem-cell-
derivedMNs. However, wewished to execute screens thatmight
capture multiple forms of MN death and therefore employed a
trophic factor withdrawal assay instead. We chose mouse rather
than human cells to carry out our large-scale screen because
cells could be rapidly produced in large numbers and carried
a reporter gene, making them easily identified and quantified.
Trophic factor withdrawal has been used by others to explore
pathways that underlie neuronal cell death, including that of
MNs (Barthe´le´my et al., 2004; Kieran et al., 2008). Furthermore,
the cell death is rapid and extensive, making it amenable to
large-scale screening. We chose to conduct our screen using
both wild-type and SOD1G93A MNs since we felt this strategy
would provide the best opportunity to identify hits that might
act in a broadly protective way, thereby giving us a better chance
of identifying molecules capable of acting therapeutically across
different ALS patient populations. For this reason, we chose to
follow up on compounds that were active in both MN types.
Kenpaullone was one of the best of these and was able to sup-
port long-term survival under multiple conditions, impressively
maintaining the integrity of the cells as assessed using a battery
of electrophysiological and morphological techniques.
Previous work has shown that enhanced death of SOD1G93A/
HB9::GFP, relative to HB9::GFP, MNs occurs after 2–3 weeks in
culture, around the time when ALS-characteristic protein aggre-
gates appear (Di Giorgio et al., 2007). Kenpaullone protects
against this delayed form of death as well. At approximately
the same time, MNs treated with kenpaullone exhibited lower
levels of mutant SOD1 protein and ubiquitin when assessed
by single-cell imaging. It may be that kenpaullone’s ability to
increase survival of the mutant MNs is ‘‘upstream’’ of SOD1
aggregation, or it may be that kenpaullone can prevent protein
aggregation, conferring an additional boost to its effects on
survival. Lowering levels of mutant SOD1 protein has been
introduced as an important strategy for developing therapeutics
targeted at the subpopulation of patients who have SOD1muta-
tions (Saito et al., 2005; Smith et al., 2006;Wang et al., 2010). Our
work suggests that it may be possible to find small drug-like
molecules that have this activity.
Kenpaullone is classified as a GSK-3 inhibitor. In many cell
types, including neurons, GSK-3 is activated during serum/
trophic factor deprivation, and inhibiting GSK-3 has been shown
to reduce neuronal apoptosis (Hetman and Xia, 2000; Linseman
et al., 2004). The connection between GSK-3 and ALS has been
demonstrated in a number of studies, and the therapeutic poten-
tial of GSK-3 inhibitors has been discussed (Koh et al., 2007,
2011). However, our data suggest that kenpaullone acts only in
part as a GSK-3 inhibitor. We tested many other GSK-3 inhibi-
tors, including those thought to be the most potent and specific,
and found that most were weakly active, at best, in promoting
MN survival. Furthermore, we carried out several experiments
in which we reduced the expression of GSK-3 and found only
relatively mild effects on survival. Kenpaullone itself was more
active than any of the knockdowns and, in fact, was able toCell Stem Cell 12, 713–726, June 6, 2013 ª2013 Elsevier Inc. 721
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Figure 7. Effect of Kenpaullone and Other
ALS Drugs on the Survival of Human MNs
Fold increase in the survival of humanMNs derived
from (A) HuES-3/Hb9::GFP ESCs, (B) wild-type
iPSCs, (C) SOD1L144F iPSCs, or (D) TDP-43M337V
iPSCs treated with DMSO, kenpaullone, olesox-
ime (Oles), or dexpramipexole (Dex). Either
HB9::GPF positive or Isl/Tuj1 double-positive cells
were counted as MNs. Data are presented as
mean ± SEM. *p < 0.05, **p < 0.01; n.s., not
significant, compared to –TF control (Student’s
t test, two-tailed). See also Figure S7.
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these results are not conclusive since there is some residual
GSK-3 activity in all of our studies, it is consistent with the pos-
sibility that kenpaullone has an additional target. To gain insight
into the identity of additional kenpaullone targets, we carried out
an extensive series of biochemical and immunocytochemical ex-
periments. We demonstrated that kenpaullone inhibits HGK, a
kinase expressed in MNs but never studied in the context of
MN disease. Inhibition of this kinase prevents the activation of
a well-known apoptosis pathway that is associated with
increased nuclear levels of phospho-c-Jun (Yao et al., 1999).
Thus, HGK potentially emerges as a therapeutic target for treat-
ing ALS.
Finally, we conducted a small human ALS ‘‘in vitro clinical
trial’’ in which we compared kenpaullone activity to that of
two compounds that failed in the clinic. Interestingly, olesoxime
had been discovered in a wild-type rat primary MN survival
screen (Bordet et al., 2007), similar to one of the assays we
used here. Dexpramipexole reportedly has not been tested
on rodent MN cultures. Both compounds had been deemedFigure 6. Mechanistic Studies of Kenpaullone Activity
(A) A comparison of MNs derived from wild-type, GSK3a-KO, GSK3b-KO, and 3/4-KO mouse ESC lines s
promoting effect when trophic factors are withdrawn. Statistics were performed comparingMN survival inTF
kenpaullone treatment further increased survival in all of the ESC lines, regardless of their genotype. Statistic
treatment toTF of the same genotype. **p < 0.01, ***p < 0.0001 (Student’s t test, two-tailed). Note that MN di
the day of plating, based on Islet/MAP2 staining (data not shown).
(B–E) Kenpaullone blocks the JNK/c-Jun-mediated cell death signaling cascade in MNs by inhibiting activity o
not CHIR99021, blocks phosphorylation and therefore activation of c-Jun, JNK, MKK4, and Tak1 in SOD1G9
*p < 0.05, **p < 0.01 ***p < 0.001, ****p < 0.0001 (two-way ANOVA). (C) Examples of phospho-c-Jun sta
SOD1G93A/Hb9::GFP MNs (green) treated with DMSO, 1 mM CHIR99021, or 10 mM kenpaullone. The ima
phosphorylation. Scale bars represent 50 mM. (D) Results from a kinase activity assay demonstrate that
CHIR99021 does not. (E) A schematic of the HGK-mediated cell death pathway shows where kenpaullone a
Data are presented as mean ± SEM. See also Figure S6.
Cell Stem Cell 12, 713–somewhat active in the standard mouse
ALS in vivo model (Bordet et al., 2007;
Gribkoff and Bozik, 2008; Sunyach
et al., 2012), but importantly, neither
had been tested on human MNs of
any variety. Even our small trial shows
that it is possible to detect important
functional differences among these
compounds when they are tested on
human MNs. For example, dexprami-
pexole was totally ineffective on any of
the human MN lines, and our resultsmight have predicted its lack of efficacy in the clinic, whereas
olesoxime had less consistent activity and somewhat smaller
effects. Kenpaullone, therefore, emerges as a preclinical com-
pound of interest, but requires additional chemical modification
to improve its potency and CNS penetration. Alternatively, it
may be possible to find an inhibitor that acts selectively on
HGK kinase that will have sufficient therapeutic activity. We
predict that more comprehensive versions of our in vitro clinical
trial in which compounds are tested on many lines of human
diseased cells, such as MNs, will be extremely useful in choos-
ing the best compounds to take into clinical studies and in
selecting patients most likely to respond to particular treat-
ments (Rubin, 2008).
EXPERIMENTAL PROCEDURES
Chemicals
Kenpaullone, LY294002, and PI-103 were purchased from Tocris. Alsterpaul-
lone, GSK-3 inhibitor VIII, and GSK-3 inhibitor IX were purchased from
Millipore. CHIR99021 was purchased from Stemgent. CHIR98014 was from
Axon Medchem. Ara-C was from Sigma-Aldrich.hows that GSK-3 reduction has a small survival-
condition of each genotype to wild-type. However,
s were performed comparing MN survival in +Ken
fferentiation rates across lines were comparable on
f an upstream activator, HGK. (B) Kenpaullone, but
3A/Hb9::GFP MNs as early as 1 hr after treatment.
ining (red) 24 hr after trophic factor withdrawal in
ges demonstrate that kenpaullone inhibits c-Jun
kenpaullone strongly inhibits HGK activity while
cts in the signaling cascade.
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Mouse ESCs were differentiated into MNs and cultured as described (Makhor-
tova et al., 2011) and plated in polyornithine-coated 96-well plates or poly-D-
lysine-coated 384-well plates. For some experiments, MNs were purified
by FACS, using a MoFlo XDP (Beckman Coulter) flow cytometer to isolate
GFP+ cells. FACS-purified MNs were plated on growth-factor-reduced
Matrigel (BD Biosciences).
Mouse MN Survival Assay
For the small molecule screen or for standard survival assays, freshly dissoci-
ated EBswere plated at a density of 8,000GFP+ cells (384-well plate) or 30,000
GFP+ cells (96-well plate) per well. Four days later, trophic factors were
removed, and individual compounds were added to the wells. For the primary
screen each compound was tested at three concentrations (0.1 mM, 1 mM, and
10mM) in duplicate. After an additional 72 hr (day 7), cellswere fixed in 4%para-
formaldehyde, stained with Hoechst 33342 (Life Technologies), and scanned
using an automated confocal microscope (PerkinElmer Opera) at 103magni-
fication. The number of MNs surviving was analyzed by counting the remaining
GFP+ cells in the whole well. Total cell numbers were obtained by counting
Hoechst-positive nuclei. A size threshold was set based on control cultures
to eliminate apoptotic MNs. Unless stated otherwise, survival is measured as
fold increase compared to cultures maintained without trophic factors.
For long-term MN survival assays, MN cultures were fed with fresh medium
and compounds every 2 days until fixation and quantification as above.
For gene-specific knockdown with shRNAs, plated MNs were infected with
lentivirus carrying shRNAs on day 2, trophic factors were withdrawn on day
4, and cells were fixed on day 7.
Human MN Differentiation and Survival Assay
Human MNs were derived from human ESCs and iPSCs as previously
described (Ding et al., 2013). After 30 days of differentiation, the cultures
were dissociated with papain solution (Worthington) and plated as single cells
on 384-well plates (Greiner) preseeded with mouse astrocytes. The medium
used was Neurobasal containing 2% B27 and 1% N2 (Life Technologies)
supplemented with 20 ng/ml of BDNF, GDNF, and CNTF (R&D Systems).
For human MN survival assays, trophic factors were removed, compounds
were added on day 6, and cells were fixed after a futher 14 day incubation.
Ara-C was present throughout the entire experiment to eliminate proliferating
progenitors. MN survival was determined by counting Hb9::GFP+ cells (HuES-
3/Hb9::GFP) and Isl+/MAP2+ or Isl+/Tuj1+ cells (human iPSCs).
Immunocytochemistry
Immunostaining was carried out using standard protocols (Makhortova et al.,
2011). The following primary antibodies were used: mouse anti-Islet (DSHB),
mouse or rabbit anti-Tuj1 (Covance), rabbit anti-MAP2 (EMD Millipore), rabbit
anti-synapsin (EMD Millipore), mouse anti-PSD95 (BD Biosciences), mouse
anti-hSOD1 (Sigma-Aldrich), goat anti-mSOD1 (R&D SYSTEMS), rabbit
anti-ubiquitin (DAKO), rabbit anti-Olig2 (EMD Millipore), anti-BrdU-Alexa 555
(BD Biosciences), rabbit anti-phospho-c-Jun (Cell Signaling), mouse anti-
phospho-JNK (Cell Signaling), rabbit anti-phospho-MKK4 (Cell Signaling),
and rabbit anti-phospho-Tak1 (Cell Signaling). Secondary antibodies conju-
gated with Alexa 488, Alexa 546, or Alexa 647 were purchased from Life
Technologies. Hoechst 33342 was used for nuclear staining.
Electrophysiology
Whole-cell voltage-clamp and current-clamp recordings were performed as
described (Son et al., 2011).
Statistical Analysis
Statistical significance was determined by Student’s t test for two groups or by
ANOVA for three or more groups. A CI of 95% was used for all comparisons.
Results are reported mean ± SD or mean ± SEM.
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